Scilex Holding (SCLX) Free Cash Flow (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Free Cash Flow of $900000.0 for Q1 2026, down 85.02% year-over-year from $6.0 million in Q1 2025, and up 105.15% on a QoQ basis from -$17.5 million in Q4 2025.
Scilex Holding (SCLX) Free Cash Flow (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Free Cash Flow for 7 consecutive years, with $900000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 85.02% year-over-year to $900000.0; the TTM figure through Mar 2026 stood at -$1.3 million (down 108.09% YoY), while the FY2025 annual figure was $3.7 million, down 80.97% from the prior year.
- Free Cash Flow came in at $900000.0 for Q1 2026 at Scilex Holding, up from -$17.5 million in the prior quarter.
- The five-year high for Free Cash Flow was $9.4 million in Q1 2024, with the low at -$17.5 million in Q4 2025.
- Average Free Cash Flow over 5 years is -$1.1 million, with a median of $2.3 million recorded in 2024.
- The largest YoY upside for Free Cash Flow was 1879.14% in 2022 against a maximum downside of 2136.1% in 2022.
- Year by year, Free Cash Flow stood at -$725000.0 in 2022, then sank by 643.59% to -$5.4 million in 2023, then soared by 147.0% to $2.5 million in 2024, then sank by 789.46% to -$17.5 million in 2025, then surged by 105.15% to $900000.0 in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered $900000.0, -$17.5 million, and $8.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.01 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 1.47 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 3.56 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 547.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 2.93 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.48 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.43 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.18 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 346.00 Mn |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 900,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 900,000.00 |
| Mar 31, 2026 | 900,000.00 |
| Dec 31, 2025 | -17.47 Mn |
| Dec 31, 2025 | -17.47 Mn |
| Sep 30, 2025 | 8.19 Mn |
| Sep 30, 2025 | 8.19 Mn |
| Jun 30, 2025 | 7.09 Mn |
| Jun 30, 2025 | 7.09 Mn |
| Mar 31, 2025 | 6.01 Mn |
| Mar 31, 2025 | 6.01 Mn |
| Dec 31, 2024 | 2.53 Mn |
| Dec 31, 2024 | 2.53 Mn |
| Sep 30, 2024 | 5.11 Mn |
| Sep 30, 2024 | 5.11 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Mar 31, 2024 | 9.39 Mn |
| Mar 31, 2024 | 9.39 Mn |
| Dec 31, 2023 | -5.39 Mn |
| Dec 31, 2023 | -5.39 Mn |